Cryptococcosis: Difference between revisions

No edit summary
Line 3: Line 3:


==Clinical Features==
==Clinical Features==
#Fever
*[[Fever]]
#Headache
*[[Headache]]
#Nausea
*[[Nausea]]
#AMS
*[[AMS]]
#Focal neurologic deficits
*[[Focal neurologic deficits]]
 
==Differential Diagnosis==


==Diagnosis==
==Diagnosis==
Line 20: Line 22:
**Cryptococcal antigen testing (95% Sn)
**Cryptococcal antigen testing (95% Sn)


==Treatment==
==Management==
{{Cryptococcus Pneumonia}}
{{Cryptococcus Pneumonia}}
{{Cryptococcus Meningitis}}
{{Cryptococcus Meningitis}}
Line 29: Line 31:
*Some patients can require longer durations of therapy depending on symptom persistence
*Some patients can require longer durations of therapy depending on symptom persistence


==Source==
==References==
*Tintinalli
 


[[Category:ID]]
[[Category:ID]]

Revision as of 14:43, 4 May 2015

Background

  • Can produce focal cerebral lesions or diffuse meningoencephalitis

Clinical Features

Differential Diagnosis

Diagnosis

  • Neuroimaging usually normal
  • CSF Studies
    • Crypto antigen (100% Sn & Sp)
    • Crypto culture (95%-100% Sn)
    • India Ink (60-80% Sn)
  • Opening pressure
    • Usually elevated; drain CSF until pressure is <20 or 50% of opening presure
  • Serum
    • Cryptococcal antigen testing (95% Sn)

Management

Pulmonary (not AIDS associated)

  • Fluconazole 400mg PO IV q24hrs x 6-12 months OR
  • Itraconazole 200mg PO q12hrs daily x 6-12 months OR
  • Voriconazole 200mg PO q12hrs x 6-12 months

Pulmonary (with AIDS)

  • Fluconazole 400mg PO q24hrs x 6-12 months

Meningitis (not AIDs associated)

  • Amphotericin B 0.7-1mg/kg IV q24hrs AND Flucytosine 25mg/kg PO q6hrs x 4 weeks
    • Followed by Fluconazole 400mg PO q24hrs x 8 weeks

Meningitis (with AIDS)

  • Amphotericin B 0.7-1mg/kg IV q24hrs AND Flucytosine 25mg/kg PO q6hrs x 2 weeks
  • Initiation of HAART is delayed by 2 to 10 weeks to minimize the risk of immune reconstitution syndrome

Disposition

  • Admit to Medicine with ID consult
  • Once the CD4 count > 200 and the patient is asymptomatic therapy x 6 months, therapy can be discontinued
  • Some patients can require longer durations of therapy depending on symptom persistence

References